Latest & greatest articles for alzheimer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alzheimer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alzheimer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Alzheimer’s disease

Alzheimer’s disease is a chronic neurodegenerative disease responsible for the majority of cases of dementia. This progressive disease disrupts memory and thinking due to an accumulation of plaques and tangles in the brain. As the disease progresses, these get progressively worse.

What causes Alzheimer’s diseases is poorly understood, although there is a strong genetic component which could account for the majority (~70%) of the risk. Other risk factors have been identified, such as depression, head injuries and hypertension. Alzheimer’s disease is typically a disease of older people.

Although Alzheimer’s disease cannot currently be cured but it can be managed. With cholinesterase inhibitors being a common intervention as well as memantine (an NMDA receptor antagonist) and psychosocial interventions.

Trip has an extensive collection of research evidence and articles relating to Alzheimer’s disease including clinical guidelines, systematic reviews, synopses, clinical trials and case reports.

Top results for alzheimer

142. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer`s disease from other cortical dementias

Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer`s disease from other cortical dementias 20802215 2011 02 17 2011 04 04 2015 11 19 1468-330X 82 3 2011 Mar Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatr. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. 240-6 10.1136/jnnp.2010.207183 Considering that most semantic dementia (SD) and frontotemporal dementia (FTD) patients (...) show no post-mortem Alzheimer's disease (AD) pathology, cerebrospinal fluid (CSF) biomarkers may be of value for distinguishing these patients from those with AD. Additionally, biomarkers may be useful for identifying patients with atypical phenotypic presentations of AD, such as posterior cortical atrophy (PCA) and primary progressive non-fluent or logopenic aphasia (PNFLA). The authors investigated CSF biomarkers (beta-amyloid 1-42 (Aβ(42)), total tau (T-tau) and phosphorylated tau (P-tau

EvidenceUpdates2011

143. Alzheimer's disease.

Alzheimer's disease. An estimated 24 million people worldwide have dementia, the majority of whom are thought to have Alzheimer's disease. Thus, Alzheimer's disease represents a major public health concern and has been identified as a research priority. Although there are licensed treatments that can alleviate symptoms of Alzheimer's disease, there is a pressing need to improve our understanding of pathogenesis to enable development of disease-modifying treatments. Methods for improving (...) diagnosis are also moving forward, but a better consensus is needed for development of a panel of biological and neuroimaging biomarkers that support clinical diagnosis. There is now strong evidence of potential risk and protective factors for Alzheimer's disease, dementia, and cognitive decline, but further work is needed to understand these better and to establish whether interventions can substantially lower these risks. In this Seminar, we provide an overview of recent evidence regarding

Lancet2011

144. Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer`s disease: a randomized controlled trial

Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer`s disease: a randomized controlled trial 20713437 2010 11 30 2011 04 01 2012 11 15 1477-0873 24 12 2010 Dec Clinical rehabilitation Clin Rehabil Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer's disease: a randomized controlled trial. 1102-11 10.1177/0269215510376004 to determine the efficacy of cognitive stimulation therapy (CST) in the treatment of neuropsychiatric (...) symptoms in patients with Alzheimer's disease. a randomized, controlled, rater-blind clinical trial. the military sanatorium. thirty-two patients with mild to moderate Alzheimer's disease exhibiting marked neuropsychiatric symptoms were included in the study. all 32 patients were randomly assigned to a cognitive stimulation therapy group (n = 16) or a control group (n = 16) for 10 weeks. the efficacy measures included the Mini Mental State Examination and the Neuropsychiatric Inventory. patients

EvidenceUpdates2011

145. Exposure to statins in early old age but not in late old age may be associated with a lower risk of developing Alzheimer's disease

Exposure to statins in early old age but not in late old age may be associated with a lower risk of developing Alzheimer's disease Exposure to statins in early old age but not in late old age may be associated with a lower risk of developing Alzheimer's disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Exposure to statins in early old age but not in late old age may be associated with a lower risk of developing Alzheimer's disease Article Text Prognosis Exposure to statins in early old age but not in late old age may be associated with a lower

Evidence-Based Mental Health2011

146. Cohort study: People with Alzheimer's disease are at increased risk of hip fracture and of mortality after hip fracture

Cohort study: People with Alzheimer's disease are at increased risk of hip fracture and of mortality after hip fracture People with Alzheimer's disease are at increased risk of hip fracture and of mortality after hip fracture | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here People with Alzheimer's disease are at increased risk of hip fracture and of mortality after hip fracture Article Text Care of older person Cohort study People with Alzheimer's disease are at increased risk of hip fracture and of

Evidence-Based Nursing (Requires free registration)2011

147. Systematic review: Pooled results of two small trials with few events show a non-significant trend towards increased risk of intracerebral haemorrhage in people with Alzheimer's disease

Systematic review: Pooled results of two small trials with few events show a non-significant trend towards increased risk of intracerebral haemorrhage in people with Alzheimer's disease Pooled results of two small trials with few events show a non-significant trend towards increased risk of intracerebral haemorrhage in people with Alzheimer's disease | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society (...) of intracerebral haemorrhage in people with Alzheimer's disease Article Text Care of older person Systematic review Pooled results of two small trials with few events show a non-significant trend towards increased risk of intracerebral haemorrhage in people with Alzheimer's disease Barbara E Harrison Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Thoonsen H , Richard E , Bentham P , et al . Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage

Evidence-Based Nursing (Requires free registration)2011

148. Aspirin in Alzheimer`s disease: increased risk of intracerebral hemorrhage: cause for concern?

Aspirin in Alzheimer`s disease: increased risk of intracerebral hemorrhage: cause for concern? 20930165 2010 10 26 2010 11 16 2016 11 22 1524-4628 41 11 2010 Nov Stroke Stroke Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern? 2690-2 10.1161/STROKEAHA.109.576975 In a randomized controlled trial in Alzheimer's disease (AD), we found a higher number of intracerebral hemorrhages (ICHs) in patients randomized to aspirin treatment. Here, we evaluate (...) the literature on the risk of ICH as a complication in patients with AD treated with aspirin. Systematic review and comparison of the occurrence of events over time between the aspirin and control group in each trial using Cox regression analysis. Estimated hazard ratios (HRs) were combined in a pooled HR. Two randomized controlled trials on aspirin for AD were found. In the Evaluation of Vascular Care in Alzheimer's Disease (EVA) trial (conducted in our center), 4.6% of patients in the group receiving

EvidenceUpdates2011

149. Genetic counseling and testing for Alzheimer disease joint practice guidelines of the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors

Genetic counseling and testing for Alzheimer disease joint practice guidelines of the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors

American College of Medical Genetics and Genomics 2011

150. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer&#39

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer' Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance and guidelines | NICE Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 Last updated: 11 May 2016 Share Save Guidance on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (CG42) and replaces NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new that affects recommendations 1.1, 1.2, 1.4, 1.5 and 1.6. Recommendation 1.3 was updated in September 2016 in NICE’s guideline on dementia (CG42

National Institute for Health and Clinical Excellence - Technology Appraisals2011

151. Responder analyses on memantine in Alzheimer's disease

Responder analyses on memantine in Alzheimer's disease Executive Summary IQWiG Reports – Commission No. A10-06 Responder analyses on memantine in Alzheimer’s disease 1 1 Translation of the executive summary of the rapid report “Responderanalysen zu Memantin bei Alzheimer Demenz” (Version 1.0; Status: 28.03.2011). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . Executive summary of rapid report A10-06 Responder analyses on memantine in Alzheimer’s disease 28.03.2011 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Version 1.0 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Responder analyses on memantine in Alzheimer’s disease Contracting agency: Federal Joint Committee Commission awarded on: 04.11.2010 Internal Commission No.: A10-06 Publisher’s address: Institute for Quality and Efficiency in Health

Institute for Quality and Efficiency in Healthcare (IQWiG)2011

152. CATIE?AD - The Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer?s Disease (AD)

CATIE?AD - The Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer?s Disease (AD) CATIE-AD 1,2 The Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer’s Disease (AD) National Institute of Mental Health (NIMH) Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease TRIAL BACKGROUND 3,4,5,6 • > 90% of pts with dementia develop at least 1 behavioural or psychiatric symptoms. Non-drug approaches to management are recommended; however (...) AD MMSE<10 - earlier trial did not find benefit QUE vs. PL for agitation in severe AD pts & was associated with significant cognitive decline 12 • Recent antipsychotic meta-analysis for off-label uses 16 References: Aleesa Carter, BSP PharmD Candidate & Julia Bareham, BSP; Loren Regier BSP, BA 1 Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. NEJM 2006; 355:1525-1538. 2 Schneider LS

RxFiles2011

153. Recommendations for defining preclinical Alzheimer's disease

Recommendations for defining preclinical Alzheimer's disease Alzheimer's & Dementia: The Journal of the Alzheimer's Association Email/Username: Password: Remember me Search Terms Search within Search Copyright © 2018 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the . Advertisements on this site do not constitute a guarantee

Alzheimer's Association2011

154. Diagnostic criteria for Alzheimer's disease

Diagnostic criteria for Alzheimer's disease Alzheimer's & Dementia: The Journal of the Alzheimer's Association Email/Username: Password: Remember me Search Terms Search within Search Copyright © 2018 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the . Advertisements on this site do not constitute a guarantee or endorsement

Alzheimer's Association2011

156. National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline.

National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline. The National Institute on Aging and the Office of Medical Applications of Research of the National Institutes of Health convened a State-of-the-Science Conference on 26-28 April 2010 to assess the available scientific evidence on prevention of cognitive decline and Alzheimer disease. This article provides the panel's assessment of the available evidence.

Annals of Internal Medicine2010

157. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer`s disease

Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer`s disease 20522869 2010 06 04 2010 06 23 2010 11 18 1468-330X 81 6 2010 Jun Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatr. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. 608-10 10.1136/jnnp.2009.197483 The clinical diagnosis (...) of dementia with Lewy bodies (DLB) is made on the basis of consensus criteria; however, the sensitivity of the criteria is relatively low. There are no generally accepted biomarkers to distinguish DLB from other dementias. Here the utility of quantification of alpha-synuclein, beta-amyloid42 (Abeta42) and tau in the CSF of patients with DLB, Alzheimer's disease (AD) and other dementias was examined. 86 patients were divided into three age and sex matched groups: DLB (n=34), AD (n=31) and other dementias

EvidenceUpdates2010

158. Preventing Alzheimer's Disease and Cognitive Decline

Preventing Alzheimer's Disease and Cognitive Decline NIH Alzheimer's and Cognitive Decline Prevention Conference - Panel Statement The programs listed are provided for reference purposes only. They were current when produced, but are no longer maintained and may now be outdated. Persons with disabilities having difficulty accessing information on this page may for assistance. Please select the to access current information. NIH State-of-the-Science Conference Preventing Alzheimer’s Disease (...) available data on prevention of Alzheimer's disease and cognitive decline. Participants: A non-Department of Health and Human Services, nonadvocate 15-member panel representing the fields of preventive medicine, geriatrics, internal medicine, neurology, neurological surgery, psychiatry, mental health, human nutrition, pharmacology, genetic medicine, nursing, health economics, health services research, and family caregiving, and a public representative. In addition, 20 experts from pertinent fields

NIH Consensus Statements2010

159. Alzheimer?s Disease 2.0

Alzheimer?s Disease 2.0 Alzheimer’s Disease 2.0 | Clinical Correlations Alzheimer’s Disease 2.0 May 12, 2010 Jeffrey Mayne MD Faculty peer reviewed Dr. Okonkwo’s post this past summer to PrimeCuts summarized ongoing research in Alzheimer’s Disease (AD), the most common cause of dementia affecting 15 million individuals worldwide and more than 5 million in the United States. It is a disease marked by cognitive deterioration that slowly breaks down one’s ability to perform activities of daily (...) diagnosis is by pathologic examination, though biopsy is not routinely performed because of the danger of the procedure, the cost, and low yield. In a patient who presents with symptoms suspicious for Alzheimer’s, brain imaging, preferably MRI, is performed. Imaging techniques differentiate AD from other causes of dementia, including cerebrovascular disease, structural diseases (i.e. chronic subdural hematoma, cerebral neoplasm, normal pressure hydrocephalus) as well as regional brain atrophy

Clinical Correlations2010

160. Alzheimer’s Disease 2.0

Alzheimer’s Disease 2.0 Alzheimer’s Disease 2.0 | Clinical Correlations Alzheimer’s Disease 2.0 April 21, 2010 Jeffery Mayne MD Faculty peer reviewed Dr. Okonkwo’s post this past summer to summarized ongoing research in Alzheimer’s Disease (AD), the most common cause of dementia affecting 15 million individuals worldwide and more than 5 million in the United States. It is a disease marked by cognitive deterioration that slowly breaks down one’s ability to perform activities of daily living (...) is by pathologic examination, though biopsy is not routinely performed because of the danger of the procedure, the cost, and low yield. In a patient who presents with symptoms suspicious for Alzheimer’s, brain imaging, preferably MRI, is performed. Imaging techniques differentiate AD from other causes of dementia, including cerebrovascular disease, structural diseases (i.e. chronic subdural hematoma, cerebral neoplasm, normal pressure hydrocephalus) as well as regional brain atrophy such as frontotemporal

Clinical Correlations2010